Table 1.
Selected microRNA signatures in lung cancer and their potential value in clinic.
| miRNA | Location | Signature | Potential value in clinic | Reference |
|---|---|---|---|---|
| let-7 | Tumor tissues | ↓ | Diagnosis marker | (7) |
| miR-17-92 | ↑ | Diagnosis marker | (14, 15) | |
| miR-218 | ↓ | Diagnosis marker | (16) | |
| miR-21 | ↑ | Diagnosis marker and metastasis marker | (17, 29) | |
| miR-34a miR-34b/c | ↓ | Diagnosis marker | (18–22) | |
| miR-200 family | ↑ | Metastasis marker | (27) | |
| miR-125a-3p/5p | ↓ | Pathological stage indicator and metastasis marker | (28) | |
| miR-106b-25 cluster | ↑ | Diagnosis marker | (30) | |
| miR-181b | ↑ | Predictor for drug resistance to Cisplatin | (31, 32) | |
| miR-181a | ||||
| miR-630 | ||||
| miR-17-5p | ↑ | Predictor for drug resistance to paclitaxel | (33) | |
| miR-145 | ↑ | Predictor for drug resistance to Gefitinib | (34) | |
| miR-25 | Body fluids | ↑ | Early diagnostic marker | (38) |
| miR-223 | ↑ | Early diagnostic marker | (38) | |
| miR-141 | ↑ | Early diagnostic marker | (39) | |
| miR-155 | ↑ | Early diagnostic marker | (40) | |
| miR-1254 | ↑ | Early diagnostic marker | (41) | |
| miR-574-5p | ↑ | |||
| miR-361-3p | ↑ | Indicator for malignant lung tumors vs benign lung tumors | (42) | |
| miR-625* | ↑ | |||
| miRNA-10b | ↑ | Indicator for positive lymph node metastasis | (43) | |
| miR-486 | ↑ | Predictor for overall survival | (44) | |
| miR-30d | ||||
| miR-1 | ||||
| miR-499 | ||||
| miR-197 | ↑ | Diagnosis marker for lung cancer patients vs normal people | (41) | |
| miR-182 | ||||
| miR-378a | Exosomes | ↑ | Diagnosis marker for lung adenocarcinoma and carcinomas patients vs healthy former smokers | (46) |
| miR-379 | ||||
| miR-139-5p | ||||
| miR-200b-5p | ||||
| miR-151a-5p | ↑ | Diagnosis marker for the lung adenocarcinoma patients vs lung granuloma patients | (46) | |
| miR-30a-3p | ||||
| miR-200b-5p | ||||
| miR-629 | ↑ | Early diagnostic marker | (47) | |
| miR-100 | ||||
| miR-154-3p | ||||